A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
BACKGROUND: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired infections. IC43 has proven immunogenicity and tolerability in healthy...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2017
|
| Sorozat: | CRITICAL CARE
21 No. 1 |
| doi: | 10.1186/s13054-017-1601-9 |
| mtmt: | 3184493 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/11629 |